Search / Trial NCT06614179

A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established

Launched by XIANGDONG CHENG · Sep 25, 2024

Trial Information

Current as of October 07, 2024

Recruiting

Keywords

Description

Secondary objective: To establish a grading model of abdominal tumors based on clinical indicators Exploratory Objective: To include CT scans in large-scale non-tumor populations for validation and to improve model accuracy Certainty

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Patients with abdominal tumors:
  • * all patients were pathologically diagnosed with abdominal tumors;
  • * The clinical case data of all patients were complete, and complete follow-up was obtained, with clear information on medical visits, operation time and survival status within 2 years. If the cause of death is unknown, it will be recorded as censored data;
  • * All patients had no history of active abdominal bleeding, no serious infection or other abdominal diseases that affected the observation of CT imaging within 3 months before surgery.
  • * Non-tumor population:
  • * all patients have complete clinical case data, complete abdominal CT, no history of malignant tumors, no serious infections or other abdominal diseases that affect the diagnosis and observation of CT imaging.
  • Exclusion Criteria:
  • * Cases in which contrast-enhanced or noncontrast CT images show unclear lesions, with significant noise and artifacts;

About Xiangdong Cheng

Xiangdong Cheng is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing novel therapeutic approaches, the organization collaborates with leading institutions and regulatory bodies to ensure rigorous trial design, patient safety, and data integrity. By leveraging a multidisciplinary team of experts, Xiangdong Cheng aims to facilitate the efficient progression of clinical studies, ultimately enhancing treatment options and improving patient outcomes in various therapeutic areas. Their commitment to excellence and ethical standards underscores their role as a pivotal player in the clinical research landscape.

Locations

Hangzhou, Zhejiang, China

Hangzhou, Zhejiang, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0